Dynamic changes of the composition of plasma HDL particles in patients with cardiac disease: Spotlight on sphingosine‐1‐phosphate/serum amyloid A ratio

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical and Experimental Pharmacology and Physiology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1440-1681.12888PMID 29112769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endurance training selectively increases high‐density lipoprotein‐bound sphingosine‐1‐phosphate in the plasma

  2018cited by this paper
• Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease

  2018cited by this paper
• Influence of HDL particles on cell-cholesterol efflux under various pathological conditions[S]

  2017cited by this paper
• Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

  2017cited by this paper
• Type 2 Diabetes in Young Females Results in Increased Serum Amyloid A and Changes to Features of High Density Lipoproteins in Both HDL2 and HDL3

  2017cited by this paper
• Serum amyloid A impairs the antiinflammatory properties of HDL.

  2016cited by this paper
• Effects of serum amyloid A on the structure and antioxidant ability of high-density lipoprotein

  2016cited by this paper
• Serum amyloid A impairs the antiinflammatory properties of HDL.

  2016cited by this paper
• Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis

  2016cited by this paper
• Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection

  2016cited by this paper
• The Relationship Among the Level of Serum Amyloid A, High‐Density Lipoprotein and Microalbuminuria in Patients With Familial Mediterranean Fever

  2016cited by this paper
• High-Density Lipoprotein Function

  2016cited by this paper
• Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

  2016cited by this paper
• HDL-C/HDL-P Ratio: A Measure of Reverse Cholesterol Transport Rather Than HDL Functionality.

  2015cited by this paper
• The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality

  2015cited by this paper
• HDL-C/HDL-P Ratio

  2015cited by this paper
• Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk.

  2015influential reference
• The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis.

  2015cited by this paper
• HDL cholesterol efflux capacity and incident cardiovascular events.

  2014cited by this paper
• Sphingosine-1-phosphate signalling as a therapeutic target for patients with abnormal glucose metabolism and ischaemic heart disease

  2014cited by this paper
• Letter from Egom regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy".

  2014cited by this paper
• Regulation of High-Density Lipoprotein Metabolism

  2014cited by this paper
• An update on the biology of sphingosine 1-phosphate receptors

  2014cited by this paper
• Effects of extended-release niacin with laropiprant in high-risk patients.

  2014cited by this paper
• Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P).

  2014cited by this paper
• High-Density Lipoprotein and Atherosclerosis Regression: Evidence From Preclinical and Clinical Studies

  2014cited by this paper
• Translation of High-Density Lipoprotein Function Into Clinical Practice: Current Prospects and Future Challenges

  2013cited by this paper
• High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy

  2013cited by this paper
• Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond1

  2013cited by this paper
• Serum amyloid A is independently related to apolipoprotein A-I but not to HDL-cholesterol in patients with angina pectoris.

  2013cited by this paper
• The relationship between serum amyloid A and apolipoprotein A‐I in high‐density lipoprotein isolated from patients with coronary heart disease

  2013cited by this paper
• Heart failure is associated with impaired anti-inflammatory and antioxidant properties of high-density lipoproteins.

  2013cited by this paper
• Hyperlipidaemia and cardiovascular disease: the quantity does not turn into quality!

  2013cited by this paper
• HDL quality or cholesterol cargo: what really matters – spotlight on sphingosine-1-phosphate-rich HDL

  2013cited by this paper
• 2011 ESC/EAS Guidelines for the Management of Dyslipidaemias

  2012cited by this paper
• Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

  2012cited by this paper
• Effects of dalcetrapib in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

  2012cited by this paper
• Sphingosine-1-phosphate signaling and its role in disease.

  2012cited by this paper
• High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A.

  2012cited by this paper
• The HDL proteome in acute coronary syndromes shifts to an inflammatory profile.

  2012cited by this paper
• The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure

  2012cited by this paper
• Uremia alters HDL composition and function.

  2011cited by this paper
• MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis

  2011cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease

  2011influential reference
• Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

  2011cited by this paper
• Influence of Apolipoprotein (Apo) A-I Structure on Nascent High Density Lipoprotein (HDL) Particle Size Distribution*

  2010cited by this paper
• Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A2[S]

  2010cited by this paper
• Impact of serum amyloid A on high density lipoprotein composition and levels

  2010cited by this paper
• Apolipoprotein A-I structural organization in high density lipoproteins isolated from human plasma

  2010cited by this paper
• Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease

  2010influential reference
• The Emerging Risk Factors Collaboration Disease Major Lipids , Apolipoproteins , and Risk of Vascular

  2009cited by this paper
• HDL Remodeling During the Acute Phase Response

  2009cited by this paper
• Major lipids, apolipoproteins, and risk of vascular disease.

  2009cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events

  2008cited by this paper
• Hyperlipidaemia and cardiovascular disease: statin update

  2007cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications

  2006cited by this paper
• Low HDL-C: a secondary target of dyslipidemia therapy.

  2005cited by this paper
• KORA - A Research Platform for Population Based Health Research

  2005cited by this paper
• Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

  2005cited by this paper
• Association of inflammatory biomarkers and cardiac troponin I with multifocal activation of coronary artery tree in the setting of non-ST-elevation acute myocardial infarction.

  2005cited by this paper
• High-density lipoprotein function recent advances.

  2005cited by this paper
• Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins.

  2005cited by this paper
• Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate.

  2003cited by this paper
• Differential Activation of Formyl Peptide Receptor-Like 1 by Peptide Ligands 1

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

  2003cited by this paper
• The role of high-density lipoproteins in oxidation and inflammation.

  2001cited by this paper
• Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.

  2001cited by this paper
• Sphingosine 1-Phosphate May Be a Major Component of Plasma Lipoproteins Responsible for the Cytoprotective Actions in Human Umbilical Vein Endothelial Cells*

  2001cited by this paper
• Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions.

  2000cited by this paper
• Evidence that lipoproteins are carriers of bioactive factors.

  1999cited by this paper
• A Seven-transmembrane, G Protein–coupled Receptor, FPRL1, Mediates the Chemotactic Activity of Serum Amyloid A for Human Phagocytic Cells

  1999cited by this paper
• The Münster Heart Study (PROCAM). Results of follow-up at 8 years.

  1998influential reference
• Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

  1986influential reference
• Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition.

  1986cited by this paper
• Cardiovascular disease and multifactorial risk: challenge of the 1980s.

  1983cited by this paper
• High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

  1977cited by this paper

• Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.

  2024cites this paper
• Quality over Quantity: A Case Based Review of HDL Function and Dysfunction

  2020cites this paper
• Acute phase reactant serum amyloid A in inflammation and other diseases.

  2019cites this paper
• The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent Regulated

  2019cites this paper